HSPA5 and cancer: In one study, MSC-Exos modified with si-GRP78 were shown to bind sorafenib, target GRP78 in cancer cells, and suppress growth, invasion, and metastasis both in vitro and in vivo, thereby reversing sorafenib resistance [63].